Here is one explanation for the pps errosion we have recently experienced. As indicated by the following there has been a very steady increase in short interest.
9/28 65,000 shares short
As U know, shorts have had their way with numerous biotech startups (amrn,vvus,arna...) so this should not be very different. EXCEPT...NVDQ appears to have a real and expanding application base for this unique technology. If they continue to succeed with their application results, this could expand to a very broad range of diagnostic & operational uses. Just the thought of being able, in real time, for a surgeon to know exactly when to stop excising tissue, or identify the exact edge of any invasive tumor or growth in the body is amazing. And vascular usage is still developing.
Well said, kkllfla. I saw them try the same pattern with ISRG when in it's infancy. It a lot of shorts lost their shorts as the stock continues huge upside moves each quarterly earnings. NVDQ, if it can develop its application base could very well have a similar market and earnings trajectory.